Generic Name and Formulations:
Methylprednisolone (as sodium succinate) 40mg, 125mg, 500mg, 1g; pwd for IV or IM inj; preservative (benzyl alcohol) and preservative-free; multi-dose vials 500mg, 1g, 2g contains preservative (benzyl alcohol).
Indications for SOLU-MEDROL:
Steroid-responsive disorders where oral therapy not feasible.
See full labeling. Individualize. Initially 10–40mg IV; subsequent doses IV or IM. For high-dose therapy: give 30mg/kg IV over 30 mins; may repeat every 4–6hrs for 48hrs.
See full labeling. Individualize. Initially 0.11–1.6mg/kg/day in 3–4 divided doses IV or IM.
Systemic fungal infections. Live vaccines. Depo-Medrol, Solu-Medrol: also premature infants (benzyl alcohol content), intrathecal administration, idiopathic thrombocytopenic purpura (IM preparations).
Not for epidural use; serious neurologic events may occur. Cerebral malaria, optic neuritis: not recommended. Latent or active amebiasis. Strongyloides infestation. Ocular herpes simplex. Cirrhosis. Tuberculosis. If exposed to chickenpox or measles, consider prophylactic passive immune therapy. Ulcerative colitis if perforation pending. Peptic ulcer. Diverticulitis. Intestinal anastomoses. Myasthenia gravis. Recent MI. CHF. Hypertension. Renal insufficiency. Osteoporosis. Diabetes. Hypothyroidism. Kaposi's sarcoma. Supplement with additional steroids in physiologic stress. Avoid abrupt cessation. May increase risk and mask signs of infection. May cause electrolyte imbalances, adrenocortical insufficiency, psychotic derangements. Alternate, intermittent, or single-daily doses at 8 AM minimize adrenal suppression. Use lowest effective dose. Monitor weight, growth, fluid and electrolyte balance. Intrasynovial: avoid previously infected or unstable joints. Pregnancy (Cat.C). Nursing mothers: not recommended.
Potentiated by CYP3A4 inhibitors (eg, ketoconazole, macrolides), cyclosporine, estrogens. Antagonized by CYP3A4 inducers (eg, barbiturates, phenytoin, carbamazepine, rifampin), cholestyramine. May potentiate cyclosporine (seizure risk). May antagonize oral anticoagulants (monitor), isoniazid. Increased risk of arrhythmias with digitalis. May need to adjust dose of antidiabetic agents. Monitor for hypokalemia with potassium-depleting drugs (eg, amphotericin B, diuretics). Concomitant neuromuscular blocking agents; increased risk of myopathy. Withdraw anticholinesterase agents at least 24hrs before initiating corticosteroid therapy. Aminoglutethimide may lead to loss of corticosteroid-induced adrenal suppression. Increased GI effects with aspirin, other NSAIDs. Caution with aspirin in hypoprothrombinemia. May suppress reactions to skin tests.
HPA axis suppression, increased susceptibility to infection, glaucoma, cataracts, secondary infections, hypokalemia, hypocalcemia, hypernatremia, hypertension, CHF, psychic disorders, myopathy, osteoporosis, peptic ulcer, dermal atrophy, increased intracranial pressure, carbohydrate intolerance. Parenteral: atrophy, flare at site; intrasynovial: septic arthritis.
Tabs 2mg—100; 4mg—100, 500; 8mg, 32mg—25; 16mg—50; Dosepak—21; Depo-Medrol multi-dose vial (20mg/mL)—1; (40mg/mL, 80mg/mL)—1, 25; Single-dose vial (40mg/mL, 80mg/mL)—1; Solu-Medrol single-dose vial (500mg, 1g)—1; (40mg, 125mg)—25; Multi-dose vial (500mg, 1g)—1; Vial with diluent (2g)—1
- 2ml of 125mg vials (Qty:1)
- appx. price $10.00
- New CDC Recommendations for Influenza Vaccination: 2015-2016
- Clinical Suspicion Leads to Uncommon Diagnosis in Patient With High Fever
- First Reported Case of Myopericarditis With Common BP Med
- Many Pregnant Women Lacking in Element Linked to Cognition in Offspring
- Severe, Persistent Joint Pain Warning Issued for Diabetes Drug Class